세계의 유방암 단클론항체 시장 보고서(2024년)

Breast Cancer Monoclonal Antibodies Global Market Report 2024

US $ 5,000 ￦ 7,234,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,500 ￦ 10,851,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,469,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

유방암 단클론항체 시장 규모는 향후 몇 년 동안 크게 성장할 것으로 예상됩니다. 2028년에는 연평균 8.3%의 복합 성장률(CAGR)로 278억 달러에 달할 것으로 예상됩니다. 향후 예상되는 성장은 몇 가지 요인에 의해 촉진될 것으로 예상됩니다. 여기에는 유방암 치료의 새로운 치료 표적의 출현, 바이오시밀러의 개발 및 활용, 병용요법 탐색, 고령화로 인한 전 세계 유방암 발병률 증가, 환자 맞춤형 의료에 대한 관심 증가 등이 포함됩니다.

유방암 발병률이 전 세계적으로 확대되고 있는 추세로 인해 유방암 단클론항체 시장의 성장이 촉진되고 있습니다. 2023년 1월 현재 미국 암 협회 통계에 따르면, 유방암 발병 건수가 눈에 띄게 증가하여 2021년 284,200건에서 2023년 30,590건으로 5.76% 증가할 것으로 예상하고 있습니다. 이러한 전 세계 유방암 발병률의 급격한 증가는 유방암 치료를 위해 특별히 고안된 단클론항체의 수요를 촉진하는 중요한 원동력이 될 것으로 예상됩니다.

유방암 단클론항체 시장의 성장이 기대되는 이유는 정부의 유방암 대책에 대한 노력과 자금 지원 때문입니다. 정부의 노력에는 유방암 관련 문제를 해결하기 위해 정부 기관이 지시하는 전략, 정책, 자금 지원 등이 포함됩니다. 특히 2023년 2월, 세계보건기구(WHO)는 세계 유방암 이니셔티브 프레임워크를 도입했습니다. 이 종합적인 프레임워크는 조기 발견, 적시 진단, 종합적인 유방암 관리를 위한 건강 증진을 옹호함으로써 2040년까지 250만 명의 생명을 구하는 것을 목표로 하고 있습니다. 이러한 정부의 개입과 재정적 지원은 유방암 단클론항체 시장을 촉진하는 데 매우 중요한 역할을 할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

• 고인플레이션이 시장에 미치는 영향
• 우크라이나·러시아 전쟁이 시장에 미치는 영향
• COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

• 세계의 시장 성장 촉진요인과 억제요인
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
• 세계의 시장 규모 실적과 성장, 2018-2023년
• 세계의 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

• 세계의 유방암 단클론항체 시장, 제품별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
• 네이키드
• 공역
• 세계의 유방암 단클론항체 시장, 치료별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
• 화학요법
• 수술과 방사선 치료
• 표적요법
• 생물학적 요법
• 호르몬요법
• 세계의 유방암 단클론항체 시장, 최종사용자별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
• 병원
• 소매 약국

제7장 지역 및 국가 분석

• 세계의 유방암 단클론항체 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
• 세계의 유방암 단클론항체 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

• 유방암 단클론항체 시장 경쟁 상황
• 유방암 단클론항체 시장 기업 개요
  • Amgen Inc.
  • Mylan NV
  • Merck &Co. Inc.
  • Novartis AG
  • GlaxoSmithKline plc

제31장 경쟁 벤치마킹

제32장 경쟁 대시보드

제33장 주요 인수합병

제34장 향후 전망과 가능성 분석

제35장 부록

ksm

영문 목차

영문목차

Breast cancer monoclonal antibodies (mAbs) represent a treatment approach employing antibodies in both early-stage and advanced breast cancer scenarios. These antibodies operate by recognizing and binding to specific proteins present on cancer cells. Each mAb targets a distinct protein, necessitating the creation of diverse mAbs to address different cancer types. Their function involves various methods to eliminate cancer cells, depending on the targeted protein.

Two primary types of breast cancer monoclonal antibodies exist: naked mAbs and conjugated mAbs. Naked mAbs refer to antibodies devoid of drugs or radioactive substances, self-contained in their structure. This category constitutes the most common type of mAb used in combating cancer. The treatments involving breast cancer monoclonal antibodies encompass a spectrum including chemotherapy, surgery, radiation therapy, targeted therapy, biologic therapy, and hormone therapy. These treatments find utilization across various healthcare sectors, including hospitals and retail pharmacies, offering diverse therapeutic options for individuals combating breast cancer.

The breast cancer monoclonal antibodies (mAbs) market research report is one of a series of new reports from The Business Research Company that provides breast cancer monoclonal antibodies (mAbs) market statistics, including breast cancer monoclonal antibodies (mAbs) industry global market size, regional shares, competitors with a breast cancer monoclonal antibodies (mAbs) market share, detailed breast cancer monoclonal antibodies (mAbs) market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer monoclonal antibodies (mAbs) industry. This breast cancer monoclonal antibodies (mAbs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The breast cancer monoclonal antibodies market size has grown strongly in recent years. It will grow from $18.97 billion in 2023 to $20.18 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historical period can be attributed to several key factors. These include the escalating prevalence of breast cancer cases, an increased awareness regarding the efficacy of breast cancer monoclonal antibodies among both healthcare professionals and the general population, the demonstrated clinical effectiveness of these treatments, and a heightened demand for these therapies from patients. These elements collectively contributed to the growth and adoption of breast cancer monoclonal antibodies during this period, fostering their acceptance and utilization in breast cancer treatment protocols.

The breast cancer monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $27.8 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the upcoming period is expected to be driven by several factors. These include the emergence of new therapeutic targets for breast cancer treatment, the development and utilization of biosimilars in therapy, the exploration of combination therapies, a rise in global breast cancer incidence due to an aging population, and an increased focus on personalized medicine tailored to individual patient needs.

The expanding incidence of breast cancer globally is poised to fuel the growth of the breast cancer monoclonal antibody market. As of January 2023, statistics from the American Cancer Society revealed a notable increase in breast cancer cases, rising from 284,200 cases in 2021 to 300,590 in 2023, signifying a 5.76% growth. This upsurge in breast cancer prevalence globally is projected to serve as a significant driver propelling the demand for monoclonal antibodies specifically designed for breast cancer treatment.

Anticipated growth in the breast cancer monoclonal antibodies market is attributed to government initiatives and funding aimed at addressing breast cancer. Government initiatives encompass strategies, policies, and funding directed by governmental bodies to tackle breast cancer-related issues. Notably, in February 2023, the World Health Organization introduced the Global Breast Cancer Initiative Framework. This comprehensive framework aims to save 2.5 million lives by 2040 by advocating health promotion for early detection, timely diagnosis, and comprehensive breast cancer management. Such governmental interventions and financial support are expected to be pivotal in driving the market for breast cancer monoclonal antibodies.

Companies operating in the breast cancer monoclonal antibodies sector are strategically investing in targeted and combination therapies, proving to be more efficacious and less toxic than traditional treatment methods. Targeted cancer therapies involve drugs that selectively interfere with molecules specifically involved in cancer cell progression. This approach seeks to eliminate cancer cells while sparing normal cells, potentially offering more effectiveness compared to conventional chemotherapy and radiotherapy. Additionally, combination therapy, involving the use of multiple drugs for a single disease, has shown promising outcomes. For instance, in May 2022, F. Hoffmann-La Roche AG launched PHESGO, an innovative breast cancer treatment combining two monoclonal antibodies, Perjeta and Herceptin, along with hyaluronidase. Administered via subcutaneous injection in tandem with intravenous chemotherapy, PHESGO caters to early and metastatic breast cancer management, pioneering a fixed-dose formulation in oncology. This strategic investment in novel therapies indicates the direction of the breast cancer monoclonal antibodies market.

In November 2021, Pfizer Inc., a leading pharmaceutical and biotechnology company based in the United States, completed the acquisition of Trillium Therapeutics for a total of $2.22 billion. This strategic acquisition represents Pfizer's endeavor to broaden its range of biologics aimed at fortifying the innate immune system to combat various hematological malignancies and solid tumors effectively. Trillium Therapeutics, headquartered in Canada, is a biopharmaceutical company with a specialized focus on pioneering immunotherapies tailored for cancer treatment, including breast cancer.

Major companies operating in the breast cancer monoclonal antibodies market include Amgen Inc., Mylan N.V., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc., Daiichi Sankyo Company Ltd., Biocad, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Array BioPharma Inc., Celldex Therapeutics Inc., Celltrion Inc., F. Hoffmann-La Roche AG, Immunomedics Inc., MacroGenics Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Puma Biotechnology Inc., Seattle Genetics Inc., AstraZeneca PLC, Eddingpharm, Eisai Co. Ltd., Galena Biopharma Inc., ImmunoGen Inc., Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Mersana Therapeutics Inc., Immunocore Limited, Immunovative Therapies Ltd.

North America was the largest region in the breast cancer monoclonal antibodies market in 2023. The regions covered in the breast cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the breast cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The breast cancer monoclonal antibodies (mAbs) market consists of sales of trastuzumab, pertuzumab, bevacizumab, and rituximab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Monoclonal Antibodies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product: Naked Mabs; Conjugated Mabs
• 2) By Treatment: Chemotherapy; Surgery & Radiation Therapy; Targeted Therapy; Biologic Therapy; Hormone Therapy
• 3) By End-User: Hospitals; Retail Pharmacies
• Companies Mentioned: Amgen Inc.; Mylan N.V.; Merck & Co. Inc.; Novartis AG; GlaxoSmithKline plc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Monoclonal Antibodies Market Characteristics

3. Breast Cancer Monoclonal Antibodies Market Trends And Strategies

4. Breast Cancer Monoclonal Antibodies Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Breast Cancer Monoclonal Antibodies Market Size and Growth

• 5.1. Global Breast Cancer Monoclonal Antibodies Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Breast Cancer Monoclonal Antibodies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Breast Cancer Monoclonal Antibodies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Breast Cancer Monoclonal Antibodies Market Segmentation

• 6.1. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Naked Mabs
• Conjugated Mabs
• 6.2. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Chemotherapy
• Surgery & Radiation Therapy
• Targeted Therapy
• Biologic Therapy
• Hormone Therapy
• 6.3. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Retail Pharmacies

7. Breast Cancer Monoclonal Antibodies Market Regional And Country Analysis

• 7.1. Global Breast Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Breast Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Breast Cancer Monoclonal Antibodies Market

• 8.1. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Breast Cancer Monoclonal Antibodies Market

• 9.1. China Breast Cancer Monoclonal Antibodies Market Overview
• 9.2. China Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Breast Cancer Monoclonal Antibodies Market

• 10.1. India Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Breast Cancer Monoclonal Antibodies Market

• 11.1. Japan Breast Cancer Monoclonal Antibodies Market Overview
• 11.2. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Breast Cancer Monoclonal Antibodies Market

• 12.1. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Breast Cancer Monoclonal Antibodies Market

• 13.1. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Breast Cancer Monoclonal Antibodies Market

• 14.1. South Korea Breast Cancer Monoclonal Antibodies Market Overview
• 14.2. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Breast Cancer Monoclonal Antibodies Market

• 15.1. Western Europe Breast Cancer Monoclonal Antibodies Market Overview
• 15.2. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Breast Cancer Monoclonal Antibodies Market

• 16.1. UK Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Breast Cancer Monoclonal Antibodies Market

• 17.1. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Breast Cancer Monoclonal Antibodies Market

• 18.1. France Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Breast Cancer Monoclonal Antibodies Market

• 19.1. Italy Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Breast Cancer Monoclonal Antibodies Market

• 20.1. Spain Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Breast Cancer Monoclonal Antibodies Market

• 21.1. Eastern Europe Breast Cancer Monoclonal Antibodies Market Overview
• 21.2. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Breast Cancer Monoclonal Antibodies Market

• 22.1. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Breast Cancer Monoclonal Antibodies Market

• 23.1. North America Breast Cancer Monoclonal Antibodies Market Overview
• 23.2. North America Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Breast Cancer Monoclonal Antibodies Market

• 24.1. USA Breast Cancer Monoclonal Antibodies Market Overview
• 24.2. USA Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Breast Cancer Monoclonal Antibodies Market

• 25.1. Canada Breast Cancer Monoclonal Antibodies Market Overview
• 25.2. Canada Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Breast Cancer Monoclonal Antibodies Market

• 26.1. South America Breast Cancer Monoclonal Antibodies Market Overview
• 26.2. South America Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Breast Cancer Monoclonal Antibodies Market

• 27.1. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Breast Cancer Monoclonal Antibodies Market

• 28.1. Middle East Breast Cancer Monoclonal Antibodies Market Overview
• 28.2. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Breast Cancer Monoclonal Antibodies Market

• 29.1. Africa Breast Cancer Monoclonal Antibodies Market Overview
• 29.2. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Breast Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

• 30.1. Breast Cancer Monoclonal Antibodies Market Competitive Landscape
• 30.2. Breast Cancer Monoclonal Antibodies Market Company Profiles
  • 30.2.1. Amgen Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Mylan N.V.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. GlaxoSmithKline plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Breast Cancer Monoclonal Antibodies Market Competitive Benchmarking

32. Global Breast Cancer Monoclonal Antibodies Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Monoclonal Antibodies Market

34. Breast Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis

• 34.1 Breast Cancer Monoclonal Antibodies Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Breast Cancer Monoclonal Antibodies Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Breast Cancer Monoclonal Antibodies Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer

관련자료